Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery

To date, IL-17A antibodies remain the only therapeutic approach to correct the abnormal activation of the IL-17A/IL-17R signaling complex. Why is it that despite the remarkable success of IL-17 antibodies, there is no small molecule antagonist of IL-17A in the clinic? Here we offer a unique approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Ting, Joey P., Tung, Frances, Antonysamy, Stephen, Wasserman, Stephen, Jones, Spencer B., Zhang, Feiyu F., Espada, Alfonso, Broughton, Howard, Chalmers, Michael J., Woodman, Michael E., Bina, Holly A., Dodge, Jeffrey A., Benach, Jordi, Zhang, Aiping, Groshong, Christopher, Manglicmot, Danalyn, Russell, Marijane, Afshar, Sepideh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766103/
https://www.ncbi.nlm.nih.gov/pubmed/29329326
http://dx.doi.org/10.1371/journal.pone.0190850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766103/
https://www.ncbi.nlm.nih.gov/pubmed/29329326
http://dx.doi.org/10.1371/journal.pone.0190850

Ejemplares similares